Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iwata, T.
Right arrow Articles by Kawakami, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iwata, T.
Right arrow Articles by Kawakami, Y.
Clinical Cancer Research Vol. 11, 3949-3957, May 15, 2005
© 2005 American Association for Cancer Research


Cancer Therapy: Preclinical

Frequent Immune Responses to a Cancer/Testis Antigen, CAGE, in Patients with Microsatellite instability–Positive Endometrial Cancer

Takashi Iwata1,2, Tomonobu Fujita1, Nobumaru Hirao1,2, Yuriko Matsuzaki1, Tsutomu Okada1, Hiroshi Mochimaru1, Nobuyuki Susumu2, Eri Matsumoto4, Kokichi Sugano4, Naohide Yamashita3, Shiro Nozawa2 and Yutaka Kawakami1

Authors' Affiliations: 1 Division of Cellular Signaling, Institute for Advanced Medical Research, 2 Department of Obstetrics and Gynecology, School of Medicine, Keio University, 3 Department of Advanced Medical Science, Institute of Medical Science, University of Tokyo, Tokyo, and 4 Oncogene Research Unit/Cancer Prevention Unit, Tochigi Cancer Center Research Institute, Tochigi, Japan

Requests for reprints: Yutaka Kawakami, Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, 35 Shinanomachi, Shinjukuku, Tokyo 160-8582, Japan. Phone: 81-3-5363-3778; Fax: 81-3-5362-9259; E-mail: yutakawa{at}sc.itc.keio.ac.jp.

Purpose: Identification of cancer/testis antigens useful for diagnosis or immunotherapy of cancers was attempted by cDNA expression cloning with patients' sera (SEREX).

Experimental Design: cDNA expression libraries made from testis or endometrial cancer cell lines were screened using sera from patients with endometrial cancer or melanoma patients immunized with dendritic cells pulsed with autologous tum or lysates. Tissue-specific expression by RT-PCR and immunogenicity by Western blotting of the bacterial recombinant antigen with sera from cancer patients were evaluated.

Results: A cancer/testis antigen, CAGE, was isolated by two independently performed SEREX. CAGE was expressed in various cancer cell lines including endometrial cancer, colon cancer, and melanoma in 7 of 10 endometrial cancer tissues and in 1 of 3 atypical endometrial hyperplasia, but not in normal tissues including the endometrium and testis. The protein expression on cancer cells was confirmed by Western blot analysis with the recombinant CAGE protein, anti-CAGE IgG antibody was detected in sera from 5 of 45 endometrial cancer, 2 of 24 melanoma, and 2 of 33 colon cancer patients, but not in sera from healthy individuals. By ELISA analysis, anti-CAGE antibody was detected in 12 of 45 endometrial cancer, 2 of 20 melanoma, and 4 of 33 colon cancer patients. Intriguingly, anti-CAGE antibody was highly positive in 7 of the 13 (53.8%) microsatellite instability (MSI)-H patients with endometrial cancer, but negative in 20 non–MSI-H patients (P = 0.001).

Conclusion: CAGE may be useful for immunotherapy and diagnosis of various cancers particularly MSI-positive endometrial cancer.

Key Words: SEREX • tumor antigen • melanoma • immunotherapy • immunodiagnosis




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
E. Hayashi, Y. Matsuzaki, G. Hasegawa, T. Yaguchi, S. Kurihara, T. Fujita, T. Kageshita, M. Sano, and Y. Kawakami
Identification of a Novel Cancer-Testis Antigen CRT2 Frequently Expressed in Various Cancers Using Representational Differential Analysis
Clin. Cancer Res., November 1, 2007; 13(21): 6267 - 6274.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. I. Risinger, G. V.R. Chandramouli, G. L. Maxwell, M. Custer, S. Pack, D. Loukinov, O. Aprelikova, T. Litzi, D. S. Schrump, S. K. Murphy, et al.
Global Expression Analysis of Cancer/Testis Genes in Uterine Cancers Reveals a High Incidence of BORIS Expression
Clin. Cancer Res., March 15, 2007; 13(6): 1713 - 1719.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Garg, D. Chaurasiya, R. Rana, N. Jagadish, D. Kanojia, N. Dudha, N. Kamran, S. Salhan, A. Bhatnagar, S. Suri, et al.
Sperm-Associated Antigen 9, a Novel Cancer Testis Antigen, Is a Potential Target for Immunotherapy in Epithelial Ovarian Cancer
Clin. Cancer Res., March 1, 2007; 13(5): 1421 - 1428.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.